Centene Corp (CNC) Earnings: Maintains FY Adjusted EPS Forecast Above $6.80

Centene Corp on Smartkarma

On Smartkarma, independent analysts from Baptista Research provide insightful coverage of Centene Corporation. In a report titled “Centene Corporation: Medicaid Managed Care Expansion and Optimization! – Major Drivers,” Centene showcased a strong financial performance in the first quarter of the year. The company surpassed expected adjusted earnings per share (EPS) at $2.26, leading to an upward revision in their full-year 2024 forecast to over $6.80 per share. While demonstrating operational efficiency and progress, the report outlined both areas of strength and ongoing challenges for Centene.

Another report by Baptista Research, “Centene Corporation: Leveraging Dual Eligibles in Medicare and Medicaid & Other Major Drivers,” highlighted positive developments and strategic maneuvers following Centene Corporation’s first quarter 2024 results. With an adjusted EPS of $2.26 exceeding expectations, the company raised its full-year 2024 EPS guidance to over $6.80. This performance reflects a strong start to the year, attributed to operational enhancements and strategic realignments aimed at sustaining and improving business operations.

A look at Centene Corp Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Centene Corporation, a multi-line managed care organization, shows a promising long-term outlook according to Smartkarma’s Smart Scores. With a high Growth score of 5, the company is positioned for strong future expansion and development. Furthermore, Centene receives favorable scores in Value, Resilience, and Momentum, indicating a solid foundation, adaptability, and positive market performance.

In contrast, Centene Corp‘s Dividend score is lower at 1, suggesting that the company may not be a top choice for dividend-seeking investors. Overall, Centene’s focus on providing Medicaid and Medicaid-related programs, along with its specialty services, underscores its commitment to the healthcare sector and potential for sustained growth in the coming years.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma